Cart
sales@molnova.com
[pThr3]-CDK5 Substrate
CAS No. 1670273-47-8
[pThr3]-CDK5 Substrate( —— )
Catalog No. M30301 CAS No. 1670273-47-8
[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate.[pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name[pThr3]-CDK5 Substrate
-
NoteResearch use only, not for human use.
-
Brief Description[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate.[pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 μM.
-
Description[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate.[pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 μM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1670273-47-8
-
Formula Weight1218.43
-
Molecular FormulaC53H100N15O15P
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameSequence:{Pro}{Lys}{pTHR}{Pro}{Lys}{Lys}{Ala}{Lys}{Lys}{Leu}
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Beaudette KN, et al. Substrate specificity characterization of a cdc2-like protein kinase purified from bovine brain. J Biol Chem. 1993 Oct 5;268(28):20825-30.
molnova catalog
related products
-
CDK7 and 9 inhibitor...
A potent, selective transcriptional CDK inhibitor with Ki of 2.3 and 0.38 nM for CDK7 and CDK9, respectively; displays >30-fold selectivity over CDK1/2/4, inhibits VEGFR2 with IC50 of 180 nM in a panel of non-CDK kinases.
-
CK7
CK7, a?Cdk2/9?inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367.
-
MBQ-167
MBQ-167 is a dual inhibitor of Rac/Cdc42 (IC50s: 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively).
